We narrowed to 19,517 results for: MUT

#1000000235

Set of high-fidelity SpCas9 variants that can be used to efficiently edit targets with practically no detectable off-target effects.

Ervin Welker

Jan. 11, 2024

Academic Institutions and Nonprofits only

#1000000249

Modular assembly of expression vectors for proximity labeling experiments.

Sven Eyckerman

Aug. 7, 2024

Academic Institutions and Nonprofits only

#1000000072

Vectors containing wild-type and mutant ORFs for studying and screening oncogenic signaling pathways.

David Sabatini, Kris Wood

March 9, 2016

Academic Institutions and Nonprofits only

#176267-AAV1

Ready-to-use AAV1 particles produced from pAAV-FLEX-P301L Tau (#176267). In addition to the viral particles, you will also receive purified pAAV-FLEX-P301L Tau plasmid DNA. EF1a-driven, Cre-dependent expression of human 2N4R microtubule-associated protein tau with P301L mutation. These AAV preparations are suitable purity for injection into animals.

Tsuneya Ikezu

You et al Neuroscience. 2019 Dec 1;422:65-74. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#113569

Pooled lentiviral plasmid library containing ~8,000 single amino acid substitution and nonsense mutant variants of p53

William Hahn, David Root

Giacomelli et al Nat Genet. 2018 Oct;50(10):1381-1387. do

Jan. 4, 2019

Academic Institutions and Nonprofits only

#58880-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Syn-ChR2(H134R)-GFP (#58880). In addition to the viral particles, you will also receive purified pAAV-Syn-ChR2(H134R)-GFP plasmid DNA. Humanized channelrhodopsin H134R mutant fused to GFP, under the control of the Synapsin promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Boyden et al Nat Neurosci. 2005 Sep . 8(9):1263-8.

June 20, 2017

Academic Institutions and Nonprofits only

#174378-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-syn-Flpo (#174378). In addition to the viral particles, you will also receive purified pAAV-syn-Flpo plasmid DNA. Syn-driven expression of the recombinase FLPo. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

Jin et al Nat Neurosci. 2024 Jan 11. doi: 10.1038/

Oct. 21, 2024

Academic Institutions and Nonprofits only

#157970-AAV.A08.T

Ready-to-use AAV2(4pMut)dHS in BSS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#62723-AAV5

Ready-to-use AAV5 particles produced from pAAV-Syn-FLEX-rc[ChrimsonR-tdTomato] (#62723). In addition to the viral particles, you will also receive purified pAAV-Syn-FLEX-rc[ChrimsonR-tdTomato] plasmid DNA. Cre-dependent ChrimsonR-tdTomato under the control of the Synapsin promoter. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

July 21, 2017

Academic Institutions and Nonprofits only

#62723-AAV1

Ready-to-use AAV1 particles produced from pAAV-Syn-FLEX-rc[ChrimsonR-tdTomato] (#62723). In addition to the viral particles, you will also receive purified pAAV-Syn-FLEX-rc[ChrimsonR-tdTomato] plasmid DNA. Cre-dependent expression of ChrimsonR-tdTomato under the control of the Synapsin promoter. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Sept. 27, 2024

Academic Institutions and Nonprofits only

#128589-AAV8

Ready-to-use AAV8 particles produced from AAV-Syn-FLPX-rc [ChrimsonR-tdTomato] (#128589). In addition to the viral particles, you will also receive purified AAV-Syn-FLPX-rc [ChrimsonR-tdTomato] plasmid DNA. Syn-driven, Flp-dependent ChrimsonR-tdTomato expression. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Feb. 14, 2022

Academic Institutions and Nonprofits only

#130909-AAV8

Ready-to-use AAV8 particles produced from AAV-CAG-FLPX-rc [ChrimsonR-tdTomato] (#130909). In addition to the viral particles, you will also receive purified AAV-CAG-FLPX-rc [ChrimsonR-tdTomato] plasmid DNA. CAG-driven, Flp-dependent expression of ChrimsonR-tdTomato. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Jan. 6, 2022

Academic Institutions and Nonprofits only

#122063-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1α1.1-ChrimsonR-GFP (#122063). In addition to the viral particles, you will also receive purified pAAV-EF1α1.1-ChrimsonR-GFP plasmid DNA. EF1a-driven expression of ChrimsonR-GFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#174296

This library contains mutations to SARS-CoV-2 Spike RBD N501Y variant in which all surface exposed residues on S RBD (Tile 2, positions 437-527) were mutated to every other amino acid.

Timothy Whitehead

Francino-Urdaniz et al Cell Rep. 2021 Aug 31;36(9):109627. doi:

Sept. 13, 2021

Academic Institutions and Nonprofits only

#174295

This library contains mutations to SARS-CoV-2 Spike RBD N501Y variant in which all surface exposed residues on S RBD (Tile 1, positions 333-436) were mutated to every other amino acid.

Timothy Whitehead

Francino-Urdaniz et al Cell Rep. 2021 Aug 31;36(9):109627. doi:

Sept. 13, 2021

Academic Institutions and Nonprofits only